About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 1NCT00959959

ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer

The purpose of this study is to determine whether TOK-001 is safe and shows biological effect in the treatment of castration resistant prostate cancer (CRPC).

Lead sponsor: LTN PHARMACEUTICALS, INC.•8 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Start Free Trial

Sponsors

Lead Sponsor

LTN PHARMACEUTICALS, INC.

Age

18 - No limit years

Sex

MALE

Healthy Volunteers

No

Inclusion Criteria

•Signed informed consent form
•Confirmed cancer of the prostate
•Progressing disease in spite of androgen ablation therapy
•Able to swallow multiple capsules

Exclusion Criteria

•Participation in another clinical trial \< 4 weeks prior to enrollment
•Metastatic disease with one or more of the following:
•* Liver involvement
•* Bone pain associated with confirmed evidence of metastases
•* Non-hepatic visceral involvement
•The following medications:
•* Prior treatment with MDV3100, abiraterone, Provenge or TAK700
•* Prior treatment with ketoconazole
•* Prior treatment with chemotherapy
•* Prior radiation therapy completed ≤ 4 weeks prior to enrollment
•The following medical conditions:
•* Active angina pectoris
•* History of Hepatitis B or Hepatitis C
•* Known HIV infection
•* Ongoing hypertension

Related studies

RECRUITINGPhase 1

A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors

NCT06926283 · Prostate Cancer, Other Solid Tumors, and more

RECRUITINGPhase 1

A Study of DXC014 in Patients With Advanced Solid Tumors.

NCT07177937 · Small Cell Lung Cancer, Melanoma, and more

RECRUITINGPhase 2

A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate

NCT06844383 · Prostate Cancer (Adenocarcinoma), mCRPC (Metastatic Castration-resistant Prostate Cancer)

RECRUITINGPhase 2

Working Out M0 Bipolar Androgen Therapy

NCT06594926 · Prostate Cancer

Lab Research Using Mini-tumors to Study Prostate Cancer Treatments

NCT07004582 · Prostate Cancer, Prostate Cancer Metastatic Disease, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: September 4, 2020Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1

Enrollment49

Start dateOct 2009

Last updatedSep 4, 2020

Condition

Prostate Cancer

Locations shown

UCLA

Los Angeles, California

San Bernardino Urological Associates

San Bernardino, California

Johns Hopkins Hospital

Baltimore, Maryland

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 4, 2020Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions